Objectives/Hypothesis: To test the osteoregenerative potential and dosing of bone morphogenetic protein-2 (BMP-2)-impregnated biomimetic scaffolds in a rat model of a mandibular defect.
INTRODUCTION
Craniofacial defects are a diverse and challenging clinical problem. Defects in the facial skeleton are currently treated with autologous tissue in the form of bone grafts or flaps 1 ; however, transfer of autologous bone is hindered by prolonged operative time, limited tissue availability, and donor site morbidity. 2 Currently, the preferred methods of reconstruction of segmental mandibular defects are bony vascularized flaps. 3 Although free flaps are a reliable means of reconstruction, they require lengthy surgeries that carry a 20.5% 4 risk of perioperative medical complications. 3, 5 An alternative means of reconstruction has the potential to spare patients life-threatening medical morbidity associated with the current standard of care.
The use of growth factors, including bone morphogenetic proteins (BMPs), transforming growth factor, fibroblast growth factor, and insulinlike growth factor, has been investigated as an alternative to autologous grafting. BMPs have been shown to stimulate bone regeneration, 6, 7 and BMP-2 is currently approved for use in spinal fusions, long bone fractures, maxillary sinus augmentation, and localized alveolar ridge defects. The concentrations of endogenous BMPs are several orders of magnitude lower (nanograms compared to milligrams) than the doses required for clinical use. 8 Supraphysiological doses required for clinical use may lead to unintended consequences such as heterotopic bone formation and pleiotropic non-bone-specific effects. 8 In part, the dosing differential is due to the acute delivery of exogenous BMP, which has a half-life of hours 9 ; however, through the use of scaffolds BMP can be delivered to bony wounds at more physiologic levels. and act as a structural support for cell colonization. Poly(lactic-co-glycolic acid) (PLGA) has been studied as a scaffold for bone regeneration both in vitro and in vivo. 11, 12 PLGA scaffolds can be precisely manipulated through three-dimensional printing 13 to mirror a craniofacial defect with tremendous accuracy. They are capable of accommodating cell migration through tightly controlled porosity, 13 and may be loaded with various growth factors for both experimental and clinical applications. 13 Importantly, PLGA scaffolds allow for manipulation of the kinetics of growth factor release through encapsulation of the growth factors in PLGA microspheres.
14 As such, the exact spatial and temporal delivery of growth factors can be tailored based on the desired effect.
Rat animal models of partial mandibular defects have been used to investigate the osteogenic potential of BMP-2, but these studies have been done in defects that do not represent large marginal mandibular defects often created in tumor ablation surgery, 15, 16 or with scaffolds that lack structural integrity to be shaped into three-dimensional structures 17 or to induce bone growth. 18 We have recently described a novel animal model for the study of composite mandibular resection in the rat, 19 and the present study employs a marginal mandibular model.
To date, the evaluation of BMP on PLGA scaffolds in marginal mandibular defects in the rat mandible has not been described. The present study seeks to determine and optimize BMP-2 dosing in a nonhealing critical-sized marginal mandibular defect in a rat model with a PLGA scaffold. We hypothesize that a critically sized marginal mandibular defect can be completely healed through delivery of BMP-2 with PLGA scaffolds, and that there exists an optimal physiologic dose of BMP-2 that maximally heals bony defects.
MATERIALS AND METHODS

Experimental Design
Forty-four Sprague-Dawley rats were divided into eight groups to investigate in vivo mandibular regeneration of a marginal defect using PLGA scaffolds loaded with BMP-2 (Tables I  and II) . To determine the lowest dose of BMP-2 necessary to regenerate the marginal mandibular defect, an additional 30 Sprague-Dawley rats were divided into five treatment groups of decreasing BMP-2 (Table I) . Additionally, one of the groups of rats was devoted to a microsphere preparation with 0.5 lg of BMP-2 on the PLGA scaffold as well as 0.5 lg of BMP-2 encapsulated in microspheres, allowing for release of the additional 0.5 lg over the course of 3 weeks 20 to determine whether manipulation of the kinetics of the BMP-2 release had an impact on bone regrowth (Table II) .
Surgical treatments consisted of creation of 5 Â 5-mm marginal defects with implantation of a PLGA scaffold loaded with a growth factor. Animals were allowed to heal for 8 weeks, and then mandibular regeneration was evaluated by microcomputed tomography (microCT) and histology. 
Scaffold Creation
Apatite-coated PLGA scaffolds were created from 85:15 PLGA (inherent viscosity, 0.61 dL/g; Birmingham Polymers) through a previously described solvent casting/particulate leaching process. 21 In brief, PLGA/chloroform solutions were mixed with 200-to 300 -lm-diameter sucrose to obtain 92% porosity (volume fraction), and compressed into 5 Â 5 Â 3-mm Teflon molds. After allowing specimens to freeze-dry overnight, the scaffolds were then submerged in three changes of distilled H 2 O to wash away the sucrose, and the scaffolds were freed from the Teflon mold. After this leaching process, all scaffolds were disinfected by immersion in 50%, 60%, and 70% ethanol for 30 minutes each followed by rinses of distilled H 2 O. Apatite coating was achieved by incubating scaffolds in simulated body fluid as described previously. All scaffolds were then allowed to dry under a laminar flow hood. For protein-loaded scaffolds, proteins were adsorbed by dropping the protein solution onto scaffolds for 20 minutes followed by further lyophilization in a freeze-drier (Labconco, Kansas City, MO). Protein-loaded microspheres were prepared by a double emulsion solvent evaporation method and incorporated into PLGA scaffolds as described previously.
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Animals and Procedures
All animal protocols were approved and overseen by the animal research committee at University of California at Los Angeles (UCLA). The UCLA facility is an American Association for Laboratory Animal Care-accredited facility. This study was carried out in strict accordance with the recommendations in the Guide for the Care and Use of Laboratory Animal of the National Institutes of Health. Scaffold regenerative abilities were tested in a previously established 17 marginal mandibular critical-size defect in 12-week-old Sprague-Dawley rats. Briefly, the animals received inhalational isoflurane until deep anesthesia was achieved. Critical-sized defects of the mandible are defined as those that will not heal spontaneously during the expected natural life of the animal. The animals were then shaved on the ventral surface of the mandible and prepped and draped in a sterile fashion. Using aseptic technique, an incision overlying and paralleling the left mandible was carried down through subcutaneous tissues. The inferior border of the mandible was then exposed by dividing the pterygomasseteric sling with electrocautery. The lingual and buccal surfaces of the mandible were then exposed through a supraperiosteal elevation of the musculature. Using a high-speed cutting burr at 3,000 RPM with copious irrigation, a 5 Â 5-mm square of bone was removed posterior to the incisor and contiguous with the inferior border of the mandible (Fig. 1) . Hemostasis was then achieved with electrocautery, and the appropriate treatment scaffold was secured within the defect with resorbable sutures (vicryl 4-0; Ethicon, Somerville, NJ) to surrounding soft tissue.
The pterygomasseteric sling was then reapproximated with the same resorbable suture, and the skin was also closed with nonresorbable nylon sutures. Rats were then allowed to recover from anesthesia and transferred to the vivarium for postoperative monitoring. Postoperatively, all animals received analgesia with subcutaneous injections of buprenorphine (0.1 mg/kg) for 72 hours postoperatively. All animals also received trimethoprim-sulfamethoxazole in the water supply for 1 week following the operation as prophylaxis against infection.
MicroCT Analysis
Animals were sacrificed after 8 weeks, and mandibles were harvested for analysis. Specimens were fixed in 10% formalin for 48 hours, and rinsed in phosphate-buffered saline prior to imaging with high-resolution microCT (lCT40; Scanco USA, Southeastern, PA). MicroCT data were collected at 50 kVp and 160 lA. Visualization and reconstruction of the data were performed using Dolphin 3D (Dolphin Imaging and Management Solutions, Chatsworth, CA). Volume analysis of new bone growth was performed using CTAn (Skyscan, Kontich, Belgium). The microCT threshold of 230 was utilized for analysis of mineralization of the mandibular defects. Volume analysis of the specimens included investigations of three volumes and two ratios: defect volume (DV), tissue volume (TV), bone volume (BV), BV/TV, and TV/DV. The DV is set as the volume of the original surgical defect (see above) that measured 2.5 Â 5 Â 5 mm and is the same across all samples. TV is the amount of new tissue growth (bone and soft tissue) within the defect volume that also includes overgrowth of bone and tissue beyond the original surgical defect when present. BV/TV represents the percentage of new tissue growth that is bone as determined by thresholding. TV/DV represents the percentage of the volume of the defect that was healed.
Histology
Ten-micrometer-thick paraffin sections (cut by microtome; McBain Instruments, Chatsworth, CA) of decalcified samples were stained with hematoxylin and eosin according to standard protocols. 22 A single sagittally cut slide was taken from the middle of the marginal defect from randomly selected samples Fig. 1 . Surgical creation of a 5 Â 5-mm marginal mandibular defect based on the inferior border of the mandible was accomplished with a high-speed cutting burr with copious irrigation (A). A poly(lactic-co-glycolic acid) scaffold with varying doses of BMP-2 (B) was then placed into the defect (C), and the pterygomasseteric sling was closed over the defect and the skin over the muscle. [Color figure can be viewed in the online issue, which is available at wileyonlinelibrary.com.]
within each experimental group to confirm the presence of compact bone. The slides were then examined with light microscopy.
Statistical Analysis
Bone healing measures (percentage defect healed, percentage bone present, bone volume healed) were compared between groups using two-sample t tests for two groups and one-way analysis of variance (ANOVA) for more than two groups. Kruskal-Wallis nonparametric ANOVA by ranks was used instead of standard ANOVA in cases where the ANOVA model assumptions were not met (non-normality and homoscedasticity). When the overall ANOVA tests were significant (P < .05), Tukey tests and confidence intervals were calculated (with family-wise error rate set at 5%) for differences in means between pairs of groups. All statistical analyses were conducted using SAS software (version 9.2; SAS Institute, Cary, NC).
RESULTS
Animals and Clinical Observations
A total of 44 rats underwent successful creation of a marginal mandibular defect in the left mandible. All animals developed some degree of postoperative swelling at the incisional site that resolved within 1 week of the operation with no functional consequences. Animals were allowed to heal 8 weeks and then sacrificed for analysis. Only one of the 44 rats (2.3%) developed an abscess and was sacrificed and excluded from analysis.
Healing of Marginal Mandibular Defects
To analyze the ability of BMP-2 to induce bone regeneration in vivo, rat 5 Â 5-mm marginal mandibular defects were implanted with control or varied doses of BMP-2 protein-coated PLGA scaffolds and analyzed at 8 weeks via microCT. PLGA is a common synthetic polymer with an established safety record in humans and not considered osteoinductive, thus allowing for direct comparison of the impact of the growth factors on healing of the defects. 23 The current experiment used decreasing doses of BMP-2 (15, 5, 1, 1 with 50% in microspheres, and 0.5 lg) per defect.
To quantitate the extent of BMP-2-induced bone regeneration, new bone volume was investigated on postmortem microCT analysis. Analysis of mandibular defects demonstrated a trend toward increasing healing of the defect volume with increasing doses of BMP-2, with 15 lg showing increased healing over all other doses (P < .01; Fig. 2 , Table I ). At a dose of 5 lg of BMP-2, complete defect healing was achieved (Figs. 2, 3, and 4A ). Closer inspection revealed that even a cortex of bone regenerates at this low dose (Fig. 3) . At a dose of 15 lg of BMP-2, there is overfill of the original defect (Fig. 4B ). Further analysis of the percentage volume healed demonstrates that with increasing doses of BMP-2 there is actually a trend toward a decrease of bone tissue, with 15 lg demonstrating a smaller percentage of bone than 0.5 lg and blank scaffolds (P < .01; Fig. 2 ). The total bone formed did not increase significantly beyond the low dose of 5 lg of BMP-2 (Fig. 5) .
Effect of Microspheres on Healing
PLGA has been used as a carrier of microspheres to lengthen the sustained release time of drugs and growth factors. 14, 24 In the present study, we used a combination of 0.5 lg of free BMP-2 on PLGA scaffolds as well as 0.5 lg of BMP-2 encapsulated in microspheres for a total dose of 1 lg and compared healing of marginal mandibular defects. The total tissue volume healed was There appeared to be an increasing trend in means, with 5 lg higher than 0.5 lg (P < .01) and 15 lg significantly higher than all other dosing for percentage defect healed (P < .01 for 15 lg vs. blank, 0.5 lg, 1 lg, and 5 lg on Tukey comparisons). Similarly, there appeared to be a trend toward decreasing percentage of bone within the healed tissue seen with increasing BMP-2 doses, with 15 lg demonstrating significantly less bone percentage than controls and 0.5 lg of BMP-2. **P < .01 on Tukey comparisons. significantly higher in the scaffolds that did not include BMP-loaded microspheres (Fig. 6 , Table II ; P ¼ .037). However, the healed tissue had a significantly higher percentage of bony healing (BV/TV; Fig. 3 ; P ¼ .015).
Histological Analysis
Sampled specimens demonstrated presence of compact bone correlating to distribution of bone seen in microCT data for BMP-2 samples at doses of 5 lg and 15 lg. Figure 3 shows sample slides demonstrating formation of cortical bone at 5 lg that is better defined than at 15 lg. Figure 3 also demonstrates lipid vacuoles within the healed defect.
DISCUSSION
BMP-2-Coated Scaffolds Heal Rat Marginal Mandibular Defects
Graft-based bone regeneration is commonly used to repair mandibular defects caused by various mechanisms, including trauma, tumor resection, osteoradionecrosis, and congenital malformations. Reconstruction of critical-sized mandibular defects is a challenging and significant problem that currently requires an invasive harvest of autologous bone, and carries with it the risk of chronic donor site morbidity in up to 11% of patients. 25 Use of manufactured biodegradable scaffolds with growth factors offers an exciting alternative to the current gold standard. BMPs have been shown to have extraordinary osteogenic potential on a variety of carriers 26 ; however, to date the rat marginal mandibular defect has yet to be healed by a BMP-laden PLGA scaffold.
The objective of this study was to evaluate the ability of PLGA scaffolds with varying doses of BMP-2 to heal marginal mandibular defects as an alternative to autogenous bone grafting. BMP-2 is perhaps the most studied osteoinductive growth factor and currently has been approved by the US Food and Drug Administration for bone healing in spinal fusion, maxillary sinus augmentation, and localized alveolar ridge defects (Infuse; One-way analysis of variance overall P value ¼ .0002. Tukey pairwise comparisons demonstrates that 5 lg of BMP-2 created significantly more bone than 0.5 lg of BMP-2 and the blank scaffold (P ¼ .008 and P < .0001, respectively). **P < .01 on Tukey comparisons.
Medtronic, Minneapolis, MN). Some reports are beginning to emerge of off-label use to reconstruct mandibular defects in humans. [27] [28] [29] [30] Despite significant study in the axial skeleton and long-bone regeneration, there is a dearth of mandibular regeneration studies. The rat serves as a relatively efficient mandibular defect model for marginal defects with the use of a PLGA. Additionally, the impact of dosing of BMP-2 has not been investigated to determine the minimal dose that will significantly induce bone formation in a mandibular defect model. 31 At a dose of 5 lg of BMP-2, PLGA scaffolds demonstrated complete healing of the defect, with evidence of cortical bone development (Figs. 2, 3 , and 4A). Higher doses of BMP-2 are not needed, as they lead to excess bony formation with a decrease in the percentage of bone-filled defect (Figs. 2 and 4B ). The successful restoration of bony mandibular defects using BMP-2-laden PLGA scaffolds demonstrated in the present study carries great promise as a viable reconstructive alternative for patients suffering from craniofacial defects.
BMP-2 induces cellular chemotaxis, proliferation, and osteogenic differentiation of both osseous and nonosseous mesenchymal cells. 32, 33 Increasing doses of BMP-2 successfully generated osseous regeneration, but also triggered nonosseous growth in our model. Histological analysis demonstrates that the tissue present in the overfilled defects contains large lipid vacuoles consistent with adipocyte stimulation (Fig. 3) . As we have shown here, increasing doses of BMP-2 generated more tissue growth in our animal, but not necessarily more bone growth. These findings may reflect a modulation of BMP-2 osteoblastic stimulation effects through local antagonists, such as noggin, gremlin, and sclerostin. [34] [35] [36] These antagonists are upregulated in a time-and dose-dependent manner, which may explain the decrease in efficacy at higher doses of BMP-2 as well as the diminished quantity of bone we encountered in our microsphere-formulated BMP-2 scaffolds. 34, 35 Potentiation of BMP-2 osteogenic capabilities has been shown to be enhanced through manipulations of these antagonists in rat femoral head defects. 37 In the present study, our data suggest that in the rat marginal mandibular defect an ideal dose exists at 5 lg. This ideal dose may reflect an ideal balance of BMP-2 and antagonists. At this dose, the defect is regenerated completely, without exuberant adipogenic stimulation (Figs. 2 and 5) . In addition to the excessive tissue production seen with higher doses of BMP-2, the quality of the bone also appears to be affected. Our histologic sections and microCT analysis demonstrate that cortical bone is formed at a 5 -lg dose, but loses definition at a higher dose of 15 lg (Figs. 3 and 4) . These data highlight the importance of establishing precise doses for species-, site-, and volume-specific defects when using BMPs, as well as the need for a more bone-specific growth factor. As this study demonstrates, by simply achieving a more physiologic presence of BMP, a more precise and higher quality regeneration can be achieved.
Our study investigated whether the rate of distribution of BMP-2 impacted the quantity and quality of bone regeneration in this animal model, under the assumption that if high doses of BMP-2 lead to exuberant growth of nonosseous cells, a sustained ideal BMP-2 dose may produce improved regeneration of bone. Use of growth factors encapsulated in microspheres embedded in PLGA scaffolds has been shown to prolong the release of the growth factor over the course of weeks. 38 Doublewalled microspheres can further provide low steady release of growth factors entirely avoiding the initial supraphysiologic burst seen with other carriers. 39 In the current study, when 50% of the dose of the BMP-2 was incorporated into microspheres there was an increase in the percentage of bone within the healed parts of the defect based on volumetric microCT analysis (BV/TV; Fig. 6 ). However, despite an increase in quality of regenerated bone produced when using this method, a smaller fraction of the defect was healed. Again, this decrease in tissue volume may also reflect a time-dependent stimulation of BMP-2 antagonists. However, it is possible that the higher density bone translates to a higher functional capacity, and our data demonstrate that a scaffold release kinetics can be further modified to promote bone healing. The present study used apatite-coated PLGA scaffolds as this coating has been shown to promote osteoblastic differentiation and bone formation. 7, 40, 41 Future studies investigating the impact of the release kinetics of growth factors and carrier attributes hold great promise in optimizing the contributions of these factors to bone regeneration.
CONCLUSION
The utilization of BMPs to restore critical-sized osseous defects of the mandibles carries great promise as an alternative therapy for patients with this problem. The present study demonstrates that our novel rat marginal Fig. 6 . A histogram comparing 1 lg of BMP-2 on a poly(lactic-coglycolic acid) scaffold to 0.5 lg of BMP-2 on a PLGA scaffold with an additional 0.5 lg of BMP-2 encapsulated in microspheres. There was significantly more healing with the unencapsulated dose of BMP-2 compared to the microsphere formulation (P ¼ .037). However, the percentage of bone filled within the tissue was significantly higher in the microsphere formulation (P ¼ .015). *P < .05 on Tukey comparisons. BV ¼ bone volume; DV ¼ defect volume; TV ¼ tissue volume. mandibular model can be successfully healed with lowdose BMP-2-loaded PLGA scaffolds. Further analysis demonstrates that the quantity and quality of bone regeneration can be significantly manipulated through adjustment of the dosing and release rate of BMP-2. The testing of novel bone-specific growth factors is critical to advancing our understanding of mandibular regeneration. Similarly, further studies are required to clarify the impact and significance of BMP-2 release kinetics, as the current study demonstrates promising but preliminary data on the use of microspheres to manipulate bony regeneration. An improved understanding of the growth factors and the physiology of bone regeneration in clinically relevant animal models will greatly improve the long-term success by which patients with craniofacial defects may be predictably and effectively treated. This technology has the potential to spare patients the significant medical risks associated with current techniques of mandibular reconstruction and autogenous bone grafting.
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